Chimeric Army Breaches the Brain: CAR-T Cells Vanquish Aggressive Tumors in Mice

Researchers affiliated with the UCLA Health Jonsson Comprehensive Cancer Center have pioneered a novel cytokine-enhanced CAR-T cell therapeutic approach. This innovative strategy demonstrates improved capacity to combat aggressive brain tumors in murine models, while simultaneously mitigating severe adverse effects that have traditionally restricted the application of immune-based interventions for glioblastoma, a particularly lethal and recalcitrant form of brain cancer.

The therapeutic mechanism involves genetically modifying CAR-T cells to secrete immune-boosting proteins, specifically IL-12 and DR-18. These cytokines serve to galvanize the host’s endogenous immune system, thereby augmenting the comprehensive counter-tumorigenic response. Investigations conducted in rodent subjects revealed enhanced tumor suppression, extending to malignancies composed of heterogeneous cell populations that frequently evade therapeutic intervention. Furthermore, the investigators observed that the integration of this treatment with a secondary CAR-T strategy targeting VEGF—a protein implicated in aberrant vascular proliferation and glioblastoma-associated edema—contributed to a reduction in deleterious side effects while maintaining robust anti-neoplastic activity.

These findings, disseminated within the pages of *Cancer Research*, a publication of the American Association for Cancer Research, posit a promising new avenue for addressing recurrent high-grade gliomas and other solid malignancies that have historically presented significant challenges for CAR-T cell therapy.

Significance

Glioblastoma presents formidable therapeutic challenges due to its capacity to suppress immune responses, its inherent cellular heterogeneity, and the development of abnormal vasculature that compromises the efficacy of immunotherapy. Although CAR-T cell therapy has revolutionized the management of specific hematological malignancies, its translation to solid tumors has been notably limited.

Addressing brain tumors, particularly glioblastoma, is complicated by the frequent antigen heterogeneity of tumor cells. This implies that not all tumor cells express the same proteins susceptible to recognition by a given targeted therapy. Our hypothesis was that an effective immunotherapy for brain tumors would necessitate the involvement of endogenously present immune cells, which possess the capability to identify a broad spectrum of target antigens, in the anti-cancer campaign.”

Yvonne Chen, PhD, co-director of the Tumor Immunology and Immunotherapy Program at the UCLA Health Jonsson Comprehensive Cancer Center and senior author of the study

Methodology

Given that brain tumors are typically characterized as immunologically “cold,” exhibiting a diminished intrinsic immune response, the research team engineered “armored CAR-T cells” designed to elicit an anti-tumor immune reaction. These CAR-T cells were constructed to target a tumor-associated antigen designated as IL-13Rα2, a protein frequently detected on glioblastoma cells, and concurrently release immune-stimulatory proteins to recruit and activate the body’s immunocompetent cells.

Subsequently, the investigators rigorously evaluated multiple permutations of these “armor” molecules within immunocompetent mouse models of glioblastoma. Comparative analyses were conducted to ascertain the impact of each configuration on tumor proliferation and immune system activity. The CAR-T cells were investigated across various orthotopic glioma models, including those engineered to exhibit variable antigen expression, thereby more accurately mirroring the heterogeneity observed in human pathologies.

Key Discoveries

Following an exhaustive assessment of various combinations, the researchers identified a particularly potent synergistic pairing: IL-12 combined with decoy-resistant IL-18, referred to as DR-18.

“The confluence of IL-12 and DR-18 orchestrates a synergistic activation of the immune system, precipitating a substantial infiltration of immune cells into the brain harboring the tumor,” stated Chen, who also holds a professorship in microbiology, immunology, and molecular genetics at UCLA and is a member of the UCLA Broad Stem Cell Research Center. “The diverse array of immune cells marshaled within the brain contributes to the elimination of the tumor, including those cancer cells that are not directly identifiable by the CAR-T cells themselves.”

This therapeutic modality demonstrated efficacy in eradicating tumors populated by cancer cells lacking the specific antigen targeted by the CAR-T cells. This represents a significant impediment in glioblastoma treatment, as tumors possess the capacity to evolve and circumvent therapies designed to target a single epitope.

Mitigating Toxicity

Recognizing the potential for IL-12 to instigate dangerous inflammation, the research team also investigated strategies to attenuate adverse effects while preserving anti-tumor efficacy.

Their investigations revealed that the incorporation of a second engineered CAR-T approach targeting VEGF served to diminish treatment-associated toxicity without compromising potent tumor control in the murine models.

“In parallel with the development of novel therapeutic agents, we consistently strive to achieve a balance between safety considerations and therapeutic efficacy,” Chen remarked. “Potent cytokines, such as IL-12 and DR-18, possess inherent toxicity potential. Consequently, we undertook comprehensive investigations to fully characterize the nature and severity of these toxicities and formulated methodologies to counteract potential safety concerns while preserving the desired anti-tumor activity.”

Implications for Patients

The research findings suggest a promising new therapeutic paradigm for the management of recurrent high-grade gliomas. The research team is currently finalizing essential preclinical studies and actively seeking funding to initiate a Phase 1 clinical trial involving patients diagnosed with this condition.

“We are profoundly encouraged by the capacity of our cytokine-enhanced CAR-T cells to eradicate not only tumor cells that express IL-13Rα2 but also those tumor cells that are not directly recognizable by the CAR-T cells,” Chen expressed. “We are enthusiastic about having developed a clinical protocol that will facilitate the translation of this therapy to clinical practice, coupled with a meticulously detailed toxicity management plan to ensure patient safety.”